CA2636837C - Combination of triazine derivatives and insulin secretion stimulators - Google Patents

Combination of triazine derivatives and insulin secretion stimulators Download PDF

Info

Publication number
CA2636837C
CA2636837C CA2636837A CA2636837A CA2636837C CA 2636837 C CA2636837 C CA 2636837C CA 2636837 A CA2636837 A CA 2636837A CA 2636837 A CA2636837 A CA 2636837A CA 2636837 C CA2636837 C CA 2636837C
Authority
CA
Canada
Prior art keywords
compound
formula
insulin secretion
pharmaceutical composition
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2636837A
Other languages
English (en)
French (fr)
Other versions
CA2636837A1 (en
Inventor
Gerard Moinet
Daniel Cravo
Didier Mesangeau
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Poxel SA
Original Assignee
Poxel SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Poxel SA filed Critical Poxel SA
Publication of CA2636837A1 publication Critical patent/CA2636837A1/en
Application granted granted Critical
Publication of CA2636837C publication Critical patent/CA2636837C/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/40—Nitrogen atoms
    • C07D251/54—Three nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2636837A 2006-01-13 2006-12-18 Combination of triazine derivatives and insulin secretion stimulators Expired - Fee Related CA2636837C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0600342A FR2896157B1 (fr) 2006-01-13 2006-01-13 Combinaison de derives de triazine et d'agents de stimulation de secretion d'insuline.
FR06/00342 2006-01-13
PCT/EP2006/012182 WO2007079914A2 (en) 2006-01-13 2006-12-18 Combination of triazine derivatives and insulin secretion stimulators

Publications (2)

Publication Number Publication Date
CA2636837A1 CA2636837A1 (en) 2007-07-19
CA2636837C true CA2636837C (en) 2013-12-10

Family

ID=36648317

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2636837A Expired - Fee Related CA2636837C (en) 2006-01-13 2006-12-18 Combination of triazine derivatives and insulin secretion stimulators

Country Status (21)

Country Link
US (1) US8227465B2 (cg-RX-API-DMAC10.html)
EP (1) EP1971339B1 (cg-RX-API-DMAC10.html)
JP (1) JP5702911B2 (cg-RX-API-DMAC10.html)
KR (1) KR20080091366A (cg-RX-API-DMAC10.html)
CN (1) CN101355949A (cg-RX-API-DMAC10.html)
AR (1) AR059030A1 (cg-RX-API-DMAC10.html)
AT (1) ATE540682T1 (cg-RX-API-DMAC10.html)
AU (1) AU2006334731B2 (cg-RX-API-DMAC10.html)
BR (1) BRPI0620923A2 (cg-RX-API-DMAC10.html)
CA (1) CA2636837C (cg-RX-API-DMAC10.html)
CY (1) CY1112674T1 (cg-RX-API-DMAC10.html)
DK (1) DK1971339T3 (cg-RX-API-DMAC10.html)
EA (1) EA016649B1 (cg-RX-API-DMAC10.html)
ES (1) ES2378469T3 (cg-RX-API-DMAC10.html)
FR (1) FR2896157B1 (cg-RX-API-DMAC10.html)
IL (1) IL192596A (cg-RX-API-DMAC10.html)
PL (1) PL1971339T3 (cg-RX-API-DMAC10.html)
PT (1) PT1971339E (cg-RX-API-DMAC10.html)
SI (1) SI1971339T1 (cg-RX-API-DMAC10.html)
WO (1) WO2007079914A2 (cg-RX-API-DMAC10.html)
ZA (1) ZA200806938B (cg-RX-API-DMAC10.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2530223T3 (es) 2008-12-12 2015-02-27 Poxel S.A.S. Combinación de insulina con derivados de triazina y su uso para tratar la diabetes
FR2948028B1 (fr) * 2009-07-17 2011-12-02 Merck Sante Sas Association d'un inhibiteur de l'echangeur sodium-proton et d'un derive amine de dihydro-1,3,5-triazine
RU2550798C2 (ru) * 2011-05-12 2015-05-10 Василий Иосифович Зоря Способ стимуляции секреции инсулина
FR2987268B1 (fr) 2012-02-28 2014-07-11 Ammtek Formulations liquides de sulfamides hypoglycemiants
TWI748945B (zh) * 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第2型糖尿病病患治療
EP3691650A1 (en) 2017-10-02 2020-08-12 Poxel Methods of treating heart failure with preserved ejection fraction
MY203360A (en) 2018-06-06 2024-06-26 Metavant Sciences Gmbh Methods of treating subjects having diabetes with chronic kidney disease
CA3103324A1 (en) * 2018-06-14 2019-12-19 Poxel Film-coated tablet comprising a triazine derivative for use in the treatment of diabetes
USD945167S1 (en) 2018-10-31 2022-03-08 Kimberly-Clark Worldwide, Inc. Paper sheet
KR20220113942A (ko) * 2019-12-13 2022-08-17 스미토모 파마 가부시키가이샤 제조성 및 용출성이 우수한 소형 정제
US12280125B2 (en) 2022-09-09 2025-04-22 Imam Abdulrahman Bin Faisal University Method for delivering insulin

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW438587B (en) 1995-06-20 2001-06-07 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
IT1276130B1 (it) 1995-11-14 1997-10-27 Gentili Ist Spa Associazione glibenclamide-metformina, composizioni farmaceutiche che la contengono e loro uso nel trattamento del diabete mellito di tipo
FR2781152B1 (fr) 1998-07-20 2001-07-06 Permatec Tech Ag Utilisation d'un polymere de type acrylique en tant qu'agent de desagregation
SI1133312T1 (sl) * 1999-06-21 2008-02-29 Lilly Co Eli Uporaba tiazolidindionov v kombinaciji z glukagonu podobnim peptidom-1 in njegovimi agonisti za zdravljenje sladkorne bolezni, neodvisne od inzulina
US6559188B1 (en) * 1999-09-17 2003-05-06 Novartis Ag Method of treating metabolic disorders especially diabetes, or a disease or condition associated with diabetes
US6586438B2 (en) * 1999-11-03 2003-07-01 Bristol-Myers Squibb Co. Antidiabetic formulation and method
ATE385421T1 (de) * 2000-01-21 2008-02-15 Novartis Pharma Gmbh Zusammensetzungen bestehend aus dipeptidylpeptidase-iv inhibitoren und antidiabetica
FR2804113B1 (fr) * 2000-01-26 2004-06-18 Lipha Derives animes de dihydro-1,3,5-triazine et leurs applications en therapeutique
ITFI20010126A1 (it) 2001-07-09 2003-01-09 Molteni & C Composizioni farmaceutiche per uso orale,contenenti,in combinazione,metformina e gliclazide
ATE361065T1 (de) * 2002-01-25 2007-05-15 Silanes Sa De Cv Lab Pharmazeutische zusammensetzung zur kontrolle des blutzuckers bei patienten mit typ 2 diabetes
US7985422B2 (en) * 2002-08-05 2011-07-26 Torrent Pharmaceuticals Limited Dosage form
US20040147564A1 (en) * 2003-01-29 2004-07-29 Rao Vinay U. Combinations of glimepiride and the thiazolidinedione for treatment of diabetes
FR2853650B1 (fr) * 2003-04-10 2006-07-07 Merck Sante Sas Procede de dedoublement d'amines utiles pour le traitement de desordres associes au syndrome d'insulino-resistance
AU2004267955A1 (en) * 2003-09-02 2005-03-10 Prosidion Ltd. Combination therapy for glycaemic control

Also Published As

Publication number Publication date
BRPI0620923A2 (pt) 2011-11-29
CY1112674T1 (el) 2016-02-10
US20100233255A1 (en) 2010-09-16
SI1971339T1 (sl) 2012-07-31
PL1971339T3 (pl) 2012-04-30
FR2896157A1 (fr) 2007-07-20
ATE540682T1 (de) 2012-01-15
IL192596A0 (en) 2009-09-22
EA200801665A1 (ru) 2008-12-30
AU2006334731B2 (en) 2012-06-21
DK1971339T3 (da) 2012-02-20
JP2009523139A (ja) 2009-06-18
IL192596A (en) 2015-07-30
US8227465B2 (en) 2012-07-24
ES2378469T3 (es) 2012-04-12
WO2007079914A2 (en) 2007-07-19
EP1971339A2 (en) 2008-09-24
PT1971339E (pt) 2012-02-20
CN101355949A (zh) 2009-01-28
AU2006334731A1 (en) 2007-07-19
AR059030A1 (es) 2008-03-12
EP1971339B1 (en) 2012-01-11
JP5702911B2 (ja) 2015-04-15
ZA200806938B (en) 2010-02-24
WO2007079914A3 (en) 2007-09-07
CA2636837A1 (en) 2007-07-19
KR20080091366A (ko) 2008-10-10
EA016649B1 (ru) 2012-06-29
FR2896157B1 (fr) 2008-09-12

Similar Documents

Publication Publication Date Title
US20140050786A1 (en) Combination of triazine derivatives and insulin sensitisers
TW201136916A (en) New uses
EP2786750B1 (en) Agent for reducing adverse side effects of kinase inhibitor
CA2636837A1 (en) Combination of triazine derivatives and insulin secretion stimulators
TWI327468B (en) Pharmaceutical composition
US20060194810A1 (en) Methods of treating ischemic related conditions
US20250361243A1 (en) Compounds and Pharmaceutical Compositions Useful for Managing Sickle Cell Disease and Conditions Related Thereto
AU2002366975B2 (en) Quinazolinone compounds in combined modalities for improved cancer treatment
MX2008008894A (en) Combination of triazine derivatives and insulin secretion stimulators
HK1128405A (en) Combination of triazine derivatives and insulin secretion stimulators
CN101415425B (zh) 甘油三酯降低剂和高胰岛素血症改善剂
MX2008008895A (en) Combination of triazine derivatives and insulin sensitisers

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20211220